A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis (PATENT PENDING)
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs Sildenafil (Primary)
- Indications Liver cirrhosis
- Focus Adverse reactions
- 30 Oct 2016 Status changed from active, no longer recruiting to discontinued.
- 12 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 02 Dec 2014 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2016 as reported by ClinicalTrials.gov record.